Medical Oncology

Uzm. Dr. Özlem Aydın İsak

Doctor and researcher Ankara Etlik Şehir Hastanesi Ankara
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionAnkara Etlik Şehir Hastanesisaglik.gov.trFrom source
  • Publications27 publicationsORCID, OpenAlexFrom source
  • ORCID0000-0003-4082-4867ORCIDFrom source
  • Last synchronised7 November 2026 00:02https://etliksehir.saglik.gov.tr/TR-864408/klinik-doktorlarimiz.html#ozlem-aydin-isaksaglik.gov.tr

Scientific work

Publications

27 publications

  1. Oxidative-Stress Biomarkers and Pathologic Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Prospective Cohort Study

    Cancers, 2026

    DOI 10.3390/cancers18121939 PMID 42352473 Open-access full textSource: ORCID

  2. Serum Vitamin D as a Predictor of Immunotherapy Response in Advanced Non-small Cell Lung Cancer

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-4-7 Open-access full textSource: OpenAlex

  3. Quantifying the Survival Benefit of Trimodality Therapy in Esophageal Squamous Cell Carcinoma: An IPTW-adjusted Retrospective Analysis

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-4-6 Open-access full textSource: OpenAlex

  4. 159eP Prognostic value of the immune checkpoint inhibitor score (IChIS) in palliative immunotherapy-treated non-small cell lung cancer: A real-world study

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.106466 Open-access full textSource: OpenAlex

  5. Real-World Evaluation of the Immune Checkpoint Inhibitor Score (IChIS) in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15197750 PMID 42882209 Open-access full textSource: OpenAlex

  6. The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancer

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04441-2 PMID 42340652 Source: OpenAlex

  7. Prognostic Significance and Primary–Metastatic Differences in VASH1 Expression, CD34-Defined Microvessel Density, and VEGF Expression in Colorectal Cancer

    International Journal of Molecular Sciences, 2026

    DOI 10.3390/ijms27146319 PMID 42511662 Open-access full textSource: OpenAlex

  8. Concordance and Discordance Between PET/CT and CEA/CA19-9 Dynamics and Their Predictive Value for Clinical Prognosis in Colorectal Cancer

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-5-1 Open-access full textSource: OpenAlex

  9. Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-29276-9 PMID 41315659 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  10. Vitamin D serum level as a predictor of response to immunotherapy for non-small cell lung cancer.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e14563 Open-access full textSource: OpenAlex

View all 27 publications